^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BI-1910

    i
    Other names: BI-1910, BI 1910, BI1910
    Associations

    News

    Trials
    Company:
    BioInvent
    Drug class:
    TNFRSF1B agonist
    Related drugs:
    Associations

    News

    Trials
    5ms
    KEYNOTE F82: BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=35, Active, not recruiting, BioInvent International AB | Recruiting --> Active, not recruiting | N=104 --> 35
    Enrollment closed • Enrollment change • First-in-human
    |
    Keytruda (pembrolizumab) • BI-1910
    2years
    BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=104, Recruiting, BioInvent International AB
    New P1/2 trial • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • BI-1910
    almost6years
    [VIRTUAL] Targeting TNFR2 for cancer immunotherapy: Ligand blocking depletors versus receptor agonists (AACR-II 2020)
    In addition, the two antibodies similarly modulated the tumor myeloid content. Based on careful MoA-characterization, two human lead candidate anti-TNFR2 antibodies are being developed for treatment of solid cancer; BI-1808, a ligand-blocking T reg depleting antibody and BI-1910, a TNFR2 agonist.
    PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    BI-1808 • BI-1910